How should I manage a female patient who refuses insulin while having a blood glucose of 302 mg/dL?

Managing Insulin Refusal with Blood Glucose of 302 mg/dL

Address the patient's refusal immediately through education and shared decision-making, while simultaneously initiating alternative glucose-lowering therapy if insulin cannot be administered, since a blood glucose of 302 mg/dL meets guideline criteria for insulin consideration but does not constitute an absolute emergency requiring forced treatment.

Immediate Assessment and Communication

First, determine why the patient is refusing insulin:

• Fear of needles or injections
• Misconceptions about insulin (e.g., "insulin means my diabetes is worse" or "insulin causes complications")
• Previous negative experiences with hypoglycemia
• Cultural or religious concerns
• Cost or access barriers
• Cognitive impairment or psychiatric issues affecting decision-making capacity

Document the patient's decision-making capacity. If she has capacity and understands the risks of refusing treatment, you must respect her autonomy while continuing education efforts.

Clinical Context Matters

The blood glucose of 302 mg/dL is significant but requires context 1:

• If symptomatic hyperglycemia is present (polyuria, polydipsia, weight loss, or signs of DKA): Insulin becomes more urgent and alternative therapies are insufficient
• If asymptomatic with A1C >10% or glucose ≥300 mg/dL: Guidelines recommend insulin as first-line injectable therapy, but alternatives exist 1
• If this is type 1 diabetes: Insulin is non-negotiable and refusal represents a life-threatening situation requiring immediate intervention

Therapeutic Approach When Insulin is Refused

For Type 2 Diabetes Without Severe Symptoms:

Initiate a GLP-1 receptor agonist or dual GIP/GLP-1 agonist immediately 1. These agents can effectively manage severe hyperglycemia even at baseline A1C of 10-12%, though evidence is limited above these levels. They offer:

• Significant glucose reduction without hypoglycemia risk
• Weight loss (which may appeal to patients refusing insulin due to weight gain concerns)
• Once-weekly dosing options for adherence

Add or optimize metformin if not contraindicated (eGFR ≥30 mL/min/1.73 m²) 1. Start with extended-release formulation to minimize GI side effects.

Consider adding an SGLT2 inhibitor for additional glucose lowering and cardiovascular/renal benefits 1.

Critical Pitfall to Avoid:

Do not use sliding scale insulin alone 2. This approach has no proven benefit, increases hypoglycemia risk, and creates large glucose fluctuations. If any insulin is eventually accepted, use basal insulin with proper titration protocols.

Education Strategy

Frame the conversation around what insulin does FOR her, not TO her:

• Insulin is the body's natural hormone that she's lacking
• Modern insulin analogues have lower hypoglycemia risk than older formulations 3
• Starting insulin now may be temporary—as glucose toxicity resolves, you can often simplify or switch to non-insulin agents 1
• Newer delivery methods (pens, 4mm needles) are less painful 3

Negotiate a trial period: "Let's try this GLP-1 medication for 2 weeks and recheck your glucose. If it's not controlled, would you reconsider insulin then?"

Monitoring and Follow-up

• Recheck blood glucose in 2-3 hours if inpatient, or within 24-48 hours if outpatient
• Set clear glucose targets and reassess therapy every 3-6 months to avoid therapeutic inertia 1
• If glucose remains >300 mg/dL or symptoms develop, insulin becomes non-negotiable and may require more intensive counseling or ethics consultation

When Insulin Refusal is Not Acceptable

If the patient has type 1 diabetes or is showing catabolic features (weight loss, ketosis, hypertriglyceridemia), insulin is the only appropriate therapy 1. In this scenario:

• Involve diabetes educators, social work, and potentially ethics consultation
• Assess for psychiatric issues or cognitive impairment affecting capacity
• Consider temporary guardianship if capacity is impaired and situation is life-threatening

The key distinction: A glucose of 302 mg/dL in an asymptomatic type 2 diabetes patient allows time for education and alternative therapies. The same glucose with symptoms of catabolism or in type 1 diabetes requires immediate insulin regardless of patient preference.